Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. März 2026 16:30 ET | Quelle: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an...
01. März 2026 09:45 ET | Quelle: Upstream Bio

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also...
26. Februar 2026 07:00 ET | Quelle: Upstream Bio

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session – WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE)...
19. Februar 2026 10:48 ET | Quelle: Research and Markets

Claudin 18.2-Targeted Immunotherapy Pipeline Market Research Report 2026: an Up-to-date Competitor Evaluation in the Field of Therapy Candidates in Research and Development

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
11. Februar 2026 06:00 ET | Quelle: Upstream Bio

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also...
08. Januar 2026 07:30 ET | Quelle: Acrivon Therapeutics, Inc

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall...
07. Dezember 2025 19:00 ET | Quelle: HUTCHMED (China) Limited

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal...
03. Dezember 2025 10:00 ET | Quelle: 4D Path

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

Trial analysis published in JNCI predicts residual cancer burden from baseline H&E slides using 4D Path's fully automated, treatment predictive platform
12. November 2025 07:00 ET | Quelle: https://immatics.com/

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable...
10. November 2025 07:30 ET | Quelle: Bluejay Therapeutics

Bluejay Therapeutics’ Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response and up to 82% Combined Endpoint of Virologic Response and ALT Normalization at Week 48 in Phase 2 Study in Chronic Hepatitis D (CHD)

Bluejay Therapeutics today announced Week 48 treatment data in chronic hepatitis D (CHD) for brelovitug (BJT-778) at AASLD 2025.

Vorherige Seite

Nächste Seite